Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.

Merkesdal, Sonja

Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. [electronic resource] - The European journal of health economics : HEPAC : health economics in prevention and care Feb 2010 - 95-104 p. digital

Publication Type: Journal Article

1618-7601

10.1007/s10198-009-0205-y doi


Aged
Antibodies, Monoclonal, Murine-Derived--economics
Antirheumatic Agents--economics
Arthritis, Rheumatoid--drug therapy
Cost-Benefit Analysis
Etanercept
Female
Germany
Humans
Immunoglobulin G--economics
Immunosuppressive Agents--economics
Male
Markov Chains
Middle Aged
Models, Econometric
Probability
Quality-Adjusted Life Years
Receptors, Tumor Necrosis Factor--therapeutic use
Rituximab
Surveys and Questionnaires
Treatment Failure